Prophylaxis News and Research RSS Feed - Prophylaxis News and Research

Key opinions leaders to discuss role of cyclophosphamide in the field of HSCT

Key opinions leaders to discuss role of cyclophosphamide in the field of HSCT

Key opinions leaders in the field of haematopoetic stem cell transplantation (HSCT) will address the role of Cyclophosphamide, an anti-cancer chemotherapy drug, during the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) that will welcome more than 4,500 delegates in the host city of Valencia, Spain from the 3rd to the 6th of April 2016. [More]
European Medicines Agency approves first-ever treatment for hereditary factor X deficiency

European Medicines Agency approves first-ever treatment for hereditary factor X deficiency

Bio Products Laboratory, Limited (BPL) today announced that the European Medicines Agency has granted marketing authorisation for Coagadex. [More]
Subcutaneous injection of raltegravir can protect against vaginal HIV transmission

Subcutaneous injection of raltegravir can protect against vaginal HIV transmission

Vaginal transmission accounts for the majority of new HIV infections worldwide. Forms of pre-exposure prophylaxis (PrEP) such as vaginal gels and vaginal rings designed to prevent HIV transmission have encountered poor efficacy in human trials due to problems with adherence. [More]
Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate. [More]
VTE patients tend to die earlier from bladder cancer

VTE patients tend to die earlier from bladder cancer

In a study of 3879 patients who underwent radical cystectomy to treat bladder cancer, 3.6% were diagnosed with a venous thromboembolism (VTE)—which occurs when a blood clot forms in a vein, potentially breaking loose and traveling to the lung—within 1 month of their surgical admission date. [More]
Idelvion approved for use in children and adults with Hemophilia B

Idelvion approved for use in children and adults with Hemophilia B

The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood. [More]
Women need antiviral medication Truvada more than men to prevent HIV infection

Women need antiviral medication Truvada more than men to prevent HIV infection

Women need daily doses of the antiviral medication Truvada to prevent HIV infection while men only need two doses per week due to the way the drug accumulates in different body tissues, according to a new study from pharmacy researchers the University of North Carolina at Chapel Hill. [More]
Dating sites helping spread HIV, study finds

Dating sites helping spread HIV, study finds

More than 60 percent of Rhode Island men who have sex with men (MSM) diagnosed with HIV in 2013 reported meeting sexual partners online in the preceding year, according to a study published today in the journal Public Health Reports. [More]
Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings. [More]
Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk for acquiring HIV. [More]
Single dose of zoledronic acid can inhibit bone loss in HIV-infected patients

Single dose of zoledronic acid can inhibit bone loss in HIV-infected patients

A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV-infected patients and that is increased during the first two years of treatment with antiretroviral therapy (ART). [More]
Dapivirine ring can help prevent HIV-1 infection in women

Dapivirine ring can help prevent HIV-1 infection in women

In an important scientific achievement for women's health, two large Phase III clinical trials -- The Ring Study and ASPIRE -- have shown that a monthly vaginal ring containing the antiretroviral drug (ARV) dapivirine can safely help prevent HIV-1 infection in women. [More]
Positive bosutinib response for elderly blast phase CML patient

Positive bosutinib response for elderly blast phase CML patient

A case study suggests that the third-generation tyrosine kinase inhibitor bosutinib may be considered as induction therapy for blast phase chronic myeloid leukaemia in older patients. [More]
Researchers confirm that cranberry extract helps fight UTIs in breastfed children under age one

Researchers confirm that cranberry extract helps fight UTIs in breastfed children under age one

Researchers from the universities of Granada (Spain) and Kvopio (Finland) have confirmed that cranberry extract helps fighting urinary tract infections (UTIs) in breastfed babies under one year of age. [More]
Researchers use quick screening method to identify, test promising anti-Ebola drugs

Researchers use quick screening method to identify, test promising anti-Ebola drugs

A quick screening method has been used for the first time in a standard open laboratory to identify and test promising anti-Ebola drugs. This approach increases the possibility of finding new therapies faster. [More]
Modeling research shows adding a vaccine to HIV/AIDS response necessary to conclusively end the epidemic

Modeling research shows adding a vaccine to HIV/AIDS response necessary to conclusively end the epidemic

Adding a vaccine to the comprehensive HIV/AIDS response is essential to conclusively ending the epidemic, according to modeling research published today. [More]
New perioperative guideline released for optimal management of geriatric patients

New perioperative guideline released for optimal management of geriatric patients

Responding to the needs of the country's growing older adult population, a new collaborative best practices guideline was released today for optimal care of older adults immediately before, during, and after surgical operations (a timeframe known as the "perioperative" period). [More]
Antibiotic prophylaxis may be recommended for dental patients

Antibiotic prophylaxis may be recommended for dental patients

When the majority of patients go in for their dental visits there is not much of a risk for bacterial infection. But for a small number of people, the use of antibiotic prophylaxis may be recommended by your dentist. [More]
Several therapies for hemophilia A, hemophilia B and hemophilia with inhibitors to be launched between 2015-2025

Several therapies for hemophilia A, hemophilia B and hemophilia with inhibitors to be launched between 2015-2025

Decision Resources Group forecasts that several therapies will launch for hemophilia A, hemophilia B and hemophilia with inhibitors in the United States and Europe during our 2015-2025 study period. [More]
Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)]. [More]
Advertisement
Advertisement